More Articles

Hospira launches infliximab biosimilar in major European markets Biosimilars/News | Posted 06/03/2015

Injectable generics specialist and biosimilars maker Hospira announced on 16 February 2015 that it was launching its infliximab biosimilar, Inflectra, in several major European markets. Inflectra,...

EMA’s clinical transparency rules come under fire Policies & Legislation | Posted 06/03/2015

The German Institute for Quality and Efficiency in Health Care (IQWiG) has once again questioned the transparency of the European Medicines Agency’s (EMA) clinical trials database.

FDA cash to develop hard-to-copy generics Generics/General | Posted 06/03/2015

The US Food and Drug Administration (FDA) is offering US$850,000 to research teams working on generics development. Funds will be split between three programmes: bioequivalence testing for long-act...

Comparison of non-originator filgrastim with Neupogen finds no difference in neutropenia recovery periods Biosimilars/Research | Posted 06/03/2015

Results of an observational study found no difference in Biocad’s non-originator filgrastim (Leucostim) compared to Neupogen in the recovery periods for patients with chemotherapy-induced neutropen...

Indian Government to launch own brand of generics Pharma News | Posted 06/03/2015

Not happy with its current control over the price of drugs in the country, the Indian Government has announced plans to launch its own brand of low cost generics.

US court invalidates asthma drug patent Generics/News | Posted 06/03/2015

The US District Court of New Jersey ruled on 13 February 2015 that the patent protecting AstraZeneca’s inhaled asthma drug Pulmicort Respules (budesonide inhalation suspension) is invalid, opening...

FDA delays meeting to evaluate infliximab biosimilar Biosimilars/News | Posted 27/02/2015

The US Food and Drug Administration (FDA) has postponed a meeting of its Arthritis Advisory Committee, which was to discuss an infliximab biosimilar.

Biosimilars of rituximab Biosimilars/General | Posted 27/02/2015

Last update: 10 November 2017Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells...